MC32 Tumor Cells Acquire Ag-specific CTL Resistance Through the Loss of CEA in a Colon Cancer Model

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2015 Apr 23

PMID 25902414

Citations 6

Authors

Sang-Yeul Lee

Jeong-Im Sin

Affiliations

Soon will be listed here.

Abstract

We previously reported that MC32 cells resist carcinoembryonic antigen (CEA) DNA vaccination by losing their antigen presentation to Ag-specific CTLs in the context of MHC class I antigens in a colon cancer therapeutic model. In this study, we selected 2 tumor cells, MC32-S2-2 and MC32-S4-2, which have the ability to form tumors in CEA DNA vaccine-immunized mice. Wild type MC32 cells grew significantly less in CEA-immunized mice (with Ag-specific CTL lytic activity) than in control mice (with no Ag-specific CTL lytic activity). However, MC32-S2-2 and MC32-S4-2 cells grew at a similar rate in both control and CEA-immunized mice, confirming their resistant status against CEA DNA vaccination. MC32-S2-2 and MC32-S4-2 cells were not susceptible to lysis by CEA-specific CD8+ T cells. Moreover, when MC32-S2-2 and MC32-S4-2 cells were used as stimulating agents of CEA-specific immune cells for IFN-γ production, these cells failed to stimulate the induction of Ag-specific IFN-γ, suggesting a loss of tumor cell recognition by Ag-specific immune cells. However, MC32-S2-2 and MC32-S4-2 cells expressed MHC class I antigens in a manner similar to that of wild type MC32 cells. Finally, Western blot assay confirmed that in MC32-S2-2 and MC32-S4-2 cells, CEA expression remained absent but mouse CEA was expressed. Taken together, these data show that MC32 cells may also be able to achieve resistance to CEA-specific CTLs by antigen loss in this model.

Citing Articles

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens.

Darrigrand R, Pierson A, Rouillon M, Renko D, Boulpicante M, Bouyssie D Commun Biol. 2021; 4(1):269.

PMID: 33649389 PMC: 7921396. DOI: 10.1038/s42003-021-01801-2.

Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model.

Han B, Ji S, Woo S, Lee J, Sin J Sci Rep. 2019; 9(1):2855.

PMID: 30814560 PMC: 6393588. DOI: 10.1038/s41598-019-39557-9.

PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.

Li Q, Liu M, Wu M, Zhou X, Wang S, Hu Y Oncol Lett. 2018; 15(4):5924-5932.

PMID: 29556312 PMC: 5844056. DOI: 10.3892/ol.2018.8075.

Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.

Donaldson B, Al-Barwani F, Pelham S, Young K, Ward V, Young S J Immunother Cancer. 2017; 5(1):69.

PMID: 28806910 PMC: 5556368. DOI: 10.1186/s40425-017-0270-1.

DNA vaccines 2014 meeting: Highlights and overview.

Ugen K, Weiner D Hum Vaccin Immunother. 2015; 11(8):1887-8.

PMID: 26158530 PMC: 4635935. DOI: 10.1080/21645515.2015.1066947.

References

Ye G, Park J, Park Y, Choi Y, Sin J . Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther. 2007; 15(8):1564-70. DOI: 10.1038/sj.mt.6300149. View

Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G . Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine. 2007; 26(1):47-58. DOI: 10.1016/j.vaccine.2007.10.060. View

Medema J, de Jong J, van Hall T, Melief C, Offringa R . Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med. 1999; 190(7):1033-8. PMC: 2195655. DOI: 10.1084/jem.190.7.1033. View

Sin J, Sung J, Suh Y, Lee A, Chung J, Sung Y . Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene. Vaccine. 1997; 15(17-18):1827-33. DOI: 10.1016/s0264-410x(97)88856-1. View

Bae S, Park Y, Park J, Choi Y, Kim M, Sin J . Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res. 2007; 13(1):341-9. DOI: 10.1158/1078-0432.CCR-06-1838. View

Hara M, Sato M, Takahashi H, Takayama S, Takeyama H . Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year. Surg Today. 2011; 41(10):1357-62. DOI: 10.1007/s00595-010-4519-2. View

Jazirehi A, Baritaki S, Koya R, Bonavida B, Economou J . Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res. 2010; 71(4):1406-17. PMC: 4180868. DOI: 10.1158/0008-5472.CAN-10-1296. View

Conforti A, Peruzzi D, Giannetti P, Biondo A, Ciliberto G, La Monica N . A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. J Immunother. 2009; 32(7):744-54. DOI: 10.1097/CJI.0b013e3181aee1b6. View

Kim S, Park M, Kim C, Sohn H, Kim H, Park J . Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine. 2008; 26(50):6433-40. DOI: 10.1016/j.vaccine.2008.08.072. View

10.

Manfredi S, Bouvier A, Lepage C, Hatem C, Dancourt V, Faivre J . Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg. 2006; 93(9):1115-22. DOI: 10.1002/bjs.5349. View

11.

Park J, Kim H, Park H, Kim C, Kim T . Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Vaccine. 2011; 29(47):8642-8. DOI: 10.1016/j.vaccine.2011.09.052. View

12.

Mennuni C, Calvaruso F, Facciabene A, Aurisicchio L, Storto M, Scarselli E . Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer. 2005; 117(3):444-55. DOI: 10.1002/ijc.21188. View

13.

Thomas D, Massague J . TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005; 8(5):369-80. DOI: 10.1016/j.ccr.2005.10.012. View

14.

Noh K, Lee Y, Jeon J, Kang T, Mao C, Wu T . Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res. 2012; 72(7):1717-27. PMC: 3319841. DOI: 10.1158/0008-5472.CAN-11-3758. View

15.

Sin J, Park J, Lee I, Park D, Choi Y, Choe J . Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides. Cancer Immunol Immunother. 2012; 61(10):1671-82. PMC: 11028417. DOI: 10.1007/s00262-012-1214-8. View

16.

Sin J, Kim H, Ahn E, Jeon Y, Park W, Lee S . Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett. 2012; 330(2):190-9. DOI: 10.1016/j.canlet.2012.11.045. View

17.

Diaz C, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S . Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med. 2013; 11:62. PMC: 3599587. DOI: 10.1186/1479-5876-11-62. View

18.

Kim H, Kwon B, Sin J . Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. PLoS One. 2014; 8(12):e83765. PMC: 3877103. DOI: 10.1371/journal.pone.0083765. View

19.

Aurisicchio L, Peruzzi D, Koo G, Wei W, La Monica N, Ciliberto G . Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. Hum Gene Ther. 2013; 25(2):121-31. PMC: 3922413. DOI: 10.1089/hum.2013.103. View

20.

Ahn E, Kim H, Han K, Sin J . A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model. Cancer Lett. 2014; 356(2 Pt B):676-85. DOI: 10.1016/j.canlet.2014.10.019. View